Contact – +1-276-477-5910
 Email – info@supplydemandmarketresearch.com

Home >>

Healthcare and Social Assistance

>>

Asia Pacific Active Pharmaceutical Ingredients API Market


Asia Pacific Active Pharmaceutical Ingredients (API) Market 2020-2026 by Synthesis (Synthetic, Biotech, HPAPI), Manufacturing Process (Captive, Merchant), Therapeutic Application, Drug Type, and Country: Trend Forecast and Growth Opportunity

Report code: SDMRHE1298206 | Industry: Healthcare and Social Assistance | Published On: 2020-06-30


Asia Pacific active pharmaceutical ingredients (API) market will grow by 9.1% annually with a total addressable market cap of $584.2 billion over 2020-2030 amid the COVID-19 pandemic.

Highlighted with 38 tables and 65 figures, this 133-page report “Asia Pacific Active Pharmaceutical Ingredients (API) Market 2020-2026 by Synthesis (Synthetic, Biotech, HPAPI), Manufacturing Process (Captive, Merchant), Therapeutic Application, Drug Type, and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire Asia Pacific API market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2015-2019 and provides forecast from 2020 till 2026 with 2019 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

In-depth qualitative analyses include identification and investigation of the following aspects:
• Market Structure
• Growth Drivers
• Restraints and Challenges
• Emerging Product Trends & Market Opportunities
• Porter’s Fiver Forces

The trend and outlook of Asia Pacific market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify Asia Pacific API market in every aspect of the classification from perspectives of Synthesis, Manufacturing Process, Therapeutic Application, Drug Type, and Country.

Based on Synthesis, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2015-2026 included in each section.
Synthetic API
• Branded Synthetic API
• Generic Synthetic API
Biotech API by Drug Type:
• Monoclonal Antibodies
• Recombinant Proteins
• Vaccines
• Other Biotech APIs
Biotech API by Customer Base:
• Innovative Biologic API
• Generic Biosimilar API
Biotech API by Expression Technology:
• Mammalian Expression
• Microbial Expression
• Yeast Expression
• Insect Expression
• Other Expression Technologies
HPAPI
• Branded HPAPI
• Generic HPAPI

Based on Manufacturing Process, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2015-2026 included in each section.
Captive Manufacturing
• Branded Captive API
• Generic Captive API
Merchant Manufacturing by Drug Type:
• Branded Merchant API
• Generic Merchant API
Merchant Manufacturing by Drug Synthesis:
• Merchant Synthetic API
• Merchant Biotech API

Based on Therapeutic Application, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2015-2026 included in each section.
• Infectious Diseases
• Oncology
• Ophthalmology
• Cardiovascular Disorders
• Central Nervous System
• Pulmonary Disorders
• Orthopedics
• Other Applications

Based on Drug Type, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2015-2026 included in each section.
• Branded Prescription Drugs
• Generic Prescription Drugs
• OTC Drugs

Geographically, the following national/local markets are fully investigated:
• Japan
• China
• South Korea
• Australia
• India
• Rest of APAC (further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, and Sri Lanka)
For each aforementioned country, detailed analysis and data for annual revenue are available for 2015-2026. The breakdown of key national markets by Synthesis, Manufacturing Process, and Therapeutic Application over the forecast years are also included.

The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.

Specifically, potential risks associated with investing in Asia Pacific API market are assayed quantitatively and qualitatively through GMD’s Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions.

Key Players (this may not be a complete list and extra companies can be added upon request):
AbbVie Inc.
Astrazeneca
Aurobindo Pharma Ltd.
Bayer Healthcare
Bioniche Animal Health
Boehringer Ingelheim
Bristol-Myers Squibb
Ceva Animal Health, Inc.
Elanco Animal Health
Eli Lilly and Company
F. Hoffmann-La Roche
Glaxosmithkline PLC
Heska Co.
Lonza Group
Merck & Co., Inc.
Novartis International AG
Pfizer, Inc.
Ranbaxy Laboratories
Sanofi
Sun Pharmaceutical Industries Ltd.
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

1  Introduction 8
1.1  Industry  Definition  and  Research  Scope 8
1.1.1  Industry  Definition 8
1.1.2  Research  Scope 9
1.2  Research  Methodology 12
1.2.1  Overview  of  Market  Research  Methodology 12
1.2.2  Market  Assumption 13
1.2.3  Secondary  Data 13
1.2.4  Primary  Data 13
1.2.5  Data  Filtration  and  Model  Design 15
1.2.6  Market  Size/Share  Estimation 16
1.2.7  Research  Limitations 17
1.3  Executive  Summary 18

2  Market  Overview  and  Dynamics 20
2.1  Market  Size  and  Forecast 20
2.2  Major  Growth  Drivers 21
2.3  Market  Restraints  and  Challenges 25
2.4  Emerging  Opportunities  and  Market  Trends 28
2.5  Porter’s  Fiver  Forces  Analysis 32

3  Segmentation  of  Asia  Pacific  Market  by  Synthesis 36
3.1  Market  Overview  by  Synthesis 36
3.2  Synthetic  API 38
3.2.1  Branded  Synthetic  API 39
3.2.2  Generic  Synthetic  API 40
3.3  Biotech  API 41
3.3.1  Biotech  API  by  Drug  Type 42
3.3.1.1  Monoclonal  Antibodies 43
3.3.1.2  Recombinant  Proteins 44
3.3.1.3  Vaccines 45
3.3.1.4  Other  Biotech  APIs 46
3.3.2  Biotech  API  by  Customer  Base 47
3.3.2.1  Innovative  Biologic  API 48
3.3.2.2  Generic  Biosimilar  API 49
3.3.3  Biotech  API  by  Expression  Technology 50
3.3.3.1  Mammalian  Expression 51
3.3.3.2  Microbial  Expression 52
3.3.3.3  Yeast  Expression 53
3.3.3.4  Insect  Expression 54
3.3.3.5  Other  Expression  Technologies 55
3.4  HPAPI 56
3.4.1  Branded  HPAPI 57
3.4.2  Generic  HPAPI 58

4  Segmentation  of  Asia  Pacific  Market  by  Manufacturing  Process 59
4.1  Market  Overview  by  Manufacturing  Process 59
4.2  Captive  Manufacturing 61
4.2.1  Branded  Captive  API 62
4.2.2  Generic  Captive  API 63
4.3  Merchant  Manufacturing 64
4.3.1  Merchant  Manufacturing  by  Drug  Type 65
4.3.1.1  Branded  Merchant  API 66
4.3.1.2  Generic  Merchant  API 67
4.3.2  Merchant  Manufacturing  by  Drug  Synthesis 68
4.3.2.1  Merchant  Synthetic  API 69
4.3.2.2  Merchant  Biotech  API 70

5  Segmentation  of  Asia  Pacific  Market  by  Therapeutic  Application 71
5.1  Market  Overview  by  Therapeutic  Application 71
5.2  Infectious  Diseases 73
5.3  Oncology 74
5.4  Ophthalmology 75
5.5  Cardiovascular  Disorders 76
5.6  Central  Nervous  System 77
5.7  Pulmonary  Disorders 78
5.8  Orthopedics 79
5.9  Other  Applications 80

6  Segmentation  of  Asia  Pacific  Market  by  Drug  Type 81
6.1  Market  Overview  by  Drug  Type 81
6.2  Branded  Prescription  Drugs 83
6.3  Generic  Prescription  Drugs 84
6.4  OTC  Drugs 85

7  Asia-Pacific  Market  2019-2026  by  Country 86
7.1  Overview  of  Asia-Pacific  Market 86
7.2  China 89
7.3  Japan 91
7.4  India 94
7.5  Australia 96
7.6  South  Korea 98
7.7  Rest  of  APAC  Region 100

8  Competitive  Landscape 102
8.1  Overview  of  Key  Vendors 102
8.2  New  Product  Launch,  Partnership,  Investment,  and  M&A 105
8.3  Company  Profiles 106
AbbVie  Inc. 106
Astrazeneca 108
Aurobindo  Pharma  Ltd. 109
Bayer  Healthcare 110
Bioniche  Animal  Health 111
Boehringer  Ingelheim 112
Bristol-Myers  Squibb 113
Ceva  Animal  Health,  Inc. 114
Elanco  Animal  Health 115
Eli  Lilly  and  Company 116
F.  Hoffmann-La  Roche 117
Glaxosmithkline  PLC 118
Heska  Co. 119
Lonza  Group 120
Merck  &  Co.,  Inc. 121
Novartis  International  AG 122
Pfizer,  Inc. 123
Ranbaxy  Laboratories 124
Sanofi 125
Sun  Pharmaceutical  Industries  Ltd. 126

9  Investing  in  Asia  Pacific  Market:  Risk  Assessment  and  Management 127
9.1  Risk  Evaluation  of  Asia  Pacific  Market 127
9.2  Critical  Success  Factors  (CSFs) 130
Related  Reports  and  Products 133
Table 1. Snapshot of Asia Pacific Active Pharmaceutical Ingredients (API) Market, 2019-2026 19
Table 2. Main Product Trends and Market Opportunities in Asia Pacific Active Pharmaceutical Ingredients (API) Market 28
Table 3. Asia Pacific Active Pharmaceutical Ingredients (API) Market by Synthesis, 2015-2026, $ bn 36
Table 4. Asia Pacific Active Pharmaceutical Ingredients (API) Market: Synthetic API by Drug Type, 2015-2026, $ bn 38
Table 5. Asia Pacific Active Pharmaceutical Ingredients (API) Market: Biotech API by Drug Type, 2015-2026, $ bn 42
Table 6. Asia Pacific Active Pharmaceutical Ingredients (API) Market: Biotech API by Customer Base, 2015-2026, $ bn 47
Table 7. Asia Pacific Active Pharmaceutical Ingredients (API) Market: Biotech API by Expression Technology, 2015-2026, $ bn 50
Table 8. Asia Pacific Active Pharmaceutical Ingredients (API) Market: HPAPI by Drug Type, 2015-2026, $ bn 56
Table 9. Asia Pacific Active Pharmaceutical Ingredients (API) Market by Manufacturing Process, 2015-2026, $ bn 59
Table 10. Asia Pacific Active Pharmaceutical Ingredients (API) Market: Captive Manufacturing by Drug Type, 2015-2026, $ bn 61
Table 11. Asia Pacific Active Pharmaceutical Ingredients (API) Market: Merchant Manufacturing by Drug Type, 2015-2026, $ bn 65
Table 12. Asia Pacific Active Pharmaceutical Ingredients (API) Market: Merchant Manufacturing by Drug Synthesis, 2015-2026, $ bn 68
Table 13. Asia Pacific Active Pharmaceutical Ingredients (API) Market by Therapeutic Application, 2015-2026, $ bn 71
Table 14. Asia Pacific Active Pharmaceutical Ingredients (API) Market by Drug Type, 2015-2026, $ bn 81
Table 15. APAC Active Pharmaceutical Ingredients (API) Market by Country, 2015-2026, $ bn 87
Table 16. China Active Pharmaceutical Ingredients (API) Market by Synthesis, 2015-2026, $ bn 90
Table 17. China Active Pharmaceutical Ingredients (API) Market by Manufacturing Process, 2015-2026, $ bn 90
Table 18. China Active Pharmaceutical Ingredients (API) Market by Therapeutic Application, 2015-2026, $ bn 90
Table 19. Japan Active Pharmaceutical Ingredients (API) Market by Synthesis, 2015-2026, $ bn 93
Table 20. Japan Active Pharmaceutical Ingredients (API) Market by Manufacturing Process, 2015-2026, $ bn 93
Table 21. Japan Active Pharmaceutical Ingredients (API) Market by Therapeutic Application, 2015-2026, $ bn 93
Table 22. India Active Pharmaceutical Ingredients (API) Market by Synthesis, 2015-2026, $ bn 95
Table 23. India Active Pharmaceutical Ingredients (API) Market by Manufacturing Process, 2015-2026, $ bn 95
Table 24. India Active Pharmaceutical Ingredients (API) Market by Therapeutic Application, 2015-2026, $ bn 95
Table 25. Australia Active Pharmaceutical Ingredients (API) Market by Synthesis, 2015-2026, $ bn 97
Table 26. Australia Active Pharmaceutical Ingredients (API) Market by Manufacturing Process, 2015-2026, $ bn 97
Table 27. Australia Active Pharmaceutical Ingredients (API) Market by Therapeutic Application, 2015-2026, $ bn 97
Table 28. South Korea Active Pharmaceutical Ingredients (API) Market by Synthesis, 2015-2026, $ bn 99
Table 29. South Korea Active Pharmaceutical Ingredients (API) Market by Manufacturing Process, 2015-2026, $ bn 99
Table 30. South Korea Active Pharmaceutical Ingredients (API) Market by Therapeutic Application, 2015-2026, $ bn 99
Table 31. Active Pharmaceutical Ingredients (API) Market in Rest of APAC by Country, 2015-2026, $ bn 101
Table 32. AbbVie Inc.: Company Snapshot 106
Table 33. AbbVie Inc.: Business Segmentation 106
Table 34. AbbVie Inc.: Product Portfolio 107
Table 35. AbbVie Inc.: Revenue, 2016-2018, $ bn 107
Table 36. AbbVie Inc.: Recent Developments 107
Table 37. Risk Evaluation for Investing in Asia Pacific Market, 2019-2026 128
Table 38. Critical Success Factors and Key Takeaways 131
 Feel free to contact us

 
Choose License Type
Select User Type


Report code




x

Use Code

SDMR20

Purchase any report

AVAIL FLAT DISCOUNT